Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

New antipsychotic drug in phase I at P&U

April 5, 1996

New antipsychotic drugs from HMR

April 5, 1996

Meiji claims improved antipsychotic agents

April 5, 1996

Pherin develops vomeropherins for anxiety

April 5, 1996

Lilly's tachykinin antagonists for chronic pain

April 5, 1996

Solvay acquires betahistine rights

March 15, 1996

Alpha2-adrenoceptor antagonists with neuroprotective effects

March 15, 1996

Astra antioxidants for hypoxia

March 15, 1996

Pierre Fabre reports antioxidants with neurologic activity

March 15, 1996

Antioxidants to treat Alzheimer's disease?

March 15, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...